Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.94 | -0.03 | 0.43 |
| FCF Yield | 1.80% | 1.07% | 0.55% | -18.18% |
| EV / EBITDA | -28.21 | -49.58 | 75.77 | -4.48 |
| Quality | ||||
| ROIC | -9.47% | 4.58% | 2.35% | -81.86% |
| Gross Margin | 85.61% | 79.09% | 89.60% | 76.39% |
| Cash Conversion Ratio | -0.59 | 0.94 | 0.03 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.34% | 91.40% | – | 3,377,842.56% |
| Free Cash Flow Growth | 92.94% | 130.99% | 103.89% | -7.23% |
| Safety | ||||
| Net Debt / EBITDA | 3.96 | 4.19 | -9.59 | 0.75 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.31 | 1.82 | 1.06 | 2.48 |
| Cash Conversion Cycle | 181.75 | 176.44 | 252.09 | 110.22 |